Reviews Avandia


No reviews yet.

Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009





Other reviews about Avandia on wordpress

Avandia: Links to stories pertaining to latest Avandia studies/reports
  by Zach Thomas
Will work to keep this page updated with the latest news regarding the diabetes drug manufactured by GlaxoSmithKline,  Avandia: Bloomberg 2/24:  Glaxo backs Avandia safety Reuters 2/24:  Glaxo 30 page […]


Avandia
  by drmarysue
The FDA announced that the diabetes drug Avandia is linked to tens of thousands of heart attacks. This information was initially reported by the FDA in 2007. Glaxo […]


Saudi Arabia suspends Avandia
  by Zach Thomas
Saudi Arabia has decided to suspend the diabetes drug Avandia (manufactured by GlaxoSmithKline) for six months after reports that "potential health risks outweigh its benefits." (Reuters) The suspension, […]


Avandia - Diabetes Drug Linked to Higher Heart Risk
  by deniedclaim
WASHINGTON — Two studies published in influential medical journals and using very different methods found that Avandia, a controversial diabetes medicine made by GlaxoSmithKline, substantially increased patients’ heart […]


Evidence continues to build against Avandia
  by Arlene Tonoff
Despite multiple studies proving the drug is dangerous and countless lawsuits in which people claim they were harmed from taking the drug, the FDA continues to allow Avandia […]


More bad news for Avandia (rosiglitazone)
  by Michael D. Shaw
If it weren't bad enough back in 2007, when Cleveland Clinic cardiologist Steven Nissen first suggested that the drug could cause heart attacks, now a new JAMA article […]


2 STUDIES: AVANDIA UNSAFE POSE HEART ATTACK AND STROKE RISK
  by jeffreynewmanlaw
Two major studies released Monday say that the diabetes drug Avandia is unsafe causing increased risk for heart attack and stroke. One of the studies was conducted by […]


Another viewpoint on Avandia
  by Michael D. Shaw
One of my advisers on this site is a wonderful physician with more than 40 years experience—based in Beverly Hills, CA. He doesn't buy into all the piling on […]


Avandia: FDA where are you?
  by jeffreynewmanlaw
Despite various studies and congressional testimony of experts revealing the risks of heart attack and stroke from the Diabetes drug Avandia, the company is still selling the product […]


Avandia
  by deniedclaim
Avandia News: What You Need to Know // Avandia (AP) (CBS) In a split decision, an FDA panel has decided to leave diabetes drug Avandia on the market despite […]



Other reviews about Avandia on web:

Find important safety information on type 2 diabetes medication and diabetes treatment side effects. Avandia


Following the reports in 2007, that Avandia can significantly increase the risk of heart attacks, the drug has been controversial. A 2010 article in Time uses the Avandia case as ... Rosiglitazone - Wikipedia, the free encyclopedia


Learn about the prescription medication Avandia (Rosiglitazone Maleate), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Avandia (Rosiglitazone Maleate) Drug Information: Uses, Side ...


Avandia (rosiglitazone) is used to treat people with type 2 (non-insulin-dependent) diabetes. Includes Avandia side effects, interactions and indications. Avandia Information from Drugs.com


Avandia Lawsuits. News & Info on Avandia; Lawyers & Attorneys for Avandia Litigation; Free Consultation with an Avandia Attorney - 1-866-952-9669 Avandia Lawyer, Attorneys, & Lawsuit Info - 866-9LAW-NOW


On July 15 -- a day after the U.S. Food and Drug Administration completed two days of hearings on the diabetes drug Avandia -- a British advisory commission on drugs ... Investigation Raises More Questions About Avandia


LONDON, Sept 8 (Reuters) - The European Medicines Agency said it was asking GlaxoSmithKline ( GSK.L ) additional questions about its diabetes drug Avandia before ... EU agency poses new questions on Glaxo's Avandia


Avandia information from Drugs.com. Avandia is used to control blood sugar levels in people with type 2 diabetes (also known as "non-insulin dependent" or "adult onset"... Avandia patient advice including side effects


Avandia Information. Avandia is a is a drug for Type 2 diabetes but has been the sugject of heart risks by the people who take it Avandia | Whats the Problem With Avandia?


Avandia increases the risk of a avandia heart attack by 43 percent and significantly increases the risk of death. Avandia is linked to a greater risk of heart attack, heart ... Avandia Linked to Heart Attacks, Cardiovascular Problems ...





Featured Reviews

Reviews Omeprazole

Prilosec Drug Description PRILOSEC (omeprazole) Delayed-Release Capsules PRILOSEC (omeprazole magnesium) For Delayed Release Oral suspension DRUG DESCRIPTION What are the possible side effects of omeprazole (Prilosec, Prilosec...
Read More  |  Review This
Reviews Deconsal CT

Deconsal CT Drug Description Deconsal® CT (phenylephrine hcl and pyrilamine maleate) Tannate Chewable Tablets DRUG DESCRIPTION What are the possible side effects of this drug? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Phenylephrine Hydrochloride Ophthalmic Solution

Neo-Synephrine Drug Description NEO-SYNEPHRINE® hydrochloride (phenylephrine hydrochloride) Ophthalmic Solution, USP Vasoconstrictor and Mydriatic Solutions 2.5% AND 10% Viscous Solution 10% For Use in Ophthalmology WARNING...
Read More  |  Review This
Reviews Activella

Activella Drug Description Activella® (estradiol/norethindrone acetate) 1.0 mg/0.5 mg 0.5 mg/0.1 mg Tablets CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular...
Read More  |  Review This
Reviews Vicodin ES

Vicodin ES Drug Description Vicodin ES® (hydrocodone bitartrate and acetaminophen) Tablets, USP 7.5 mg/750 mg DRUG DESCRIPTION Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration. Hydrocodone...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....